Non-Invasive Prenatal Testing Market Size Grows at a CAGR of 13.67%

Introduction

Straits Research released its highly anticipated report, “Global Non-invasive Prenatal Testing Market Size & Outlook, 2026-2034”. According to the study, the global market size is valued at USD 5.37 billion in 2025 and is projected to expand to USD 16.94 billion by 2034, registering a compound annual growth rate (CAGR) of 13.67%.

Market Dynamics

The growth of the global non-invasive prenatal testing market is primarily driven by the rising maternal age at the time of pregnancy, which increases the risk of chromosomal abnormalities. According to the National Center for Biotechnology Information (NCBI), the likelihood of Down syndrome increases from 1 in 1,300 at age 25 to 1 in 365 at age 35, and nearly 1 in 30 at age 40. As a result, the growing trend of delayed pregnancies globally has led to a higher demand for accurate and safe prenatal screening methods such as NIPT. Additionally, the growing preference for minimally invasive diagnostic procedures among expectant mothers, driven by their safety, high accuracy, and early detection capabilities, is further propelling market growth.

However, the high cost of NIPT remains a restraint, particularly in developing regions where healthcare infrastructure and reimbursement policies are still evolving. Limited access to advanced testing facilities and a lack of awareness among pregnant women also hinder widespread adoption. On the other hand, expanding applications of NIPT beyond the detection of common trisomies are creating substantial growth opportunities. Technological advancements now enable the detection of microdeletions, sex chromosome abnormalities, and even single gene disorders, thereby broadening the clinical utility of these tests. Moreover, the market continues to expand as continuous innovations, strategic collaborations among biotech firms, and supportive regulatory frameworks accelerate product availability and affordability. As healthcare systems increasingly prioritize preventive and personalized maternal care, the NIPT market is expected to experience robust growth in the coming years, driven by technological progress, broader test applications, and rising global awareness of prenatal health.

Market Highlights

• Product: The services segment is expected to register the fastest CAGR of 14.31% during the forecast period.
• Application: The microdeletion syndrome segment is projected to grow with the fastest CAGR of 14.96%.
• End User: The diagnostic laboratories segment is forecasted to grow at a CAGR of 15.07%, owing to growing dependence on specialized laboratories for advanced genetic testing.
• Regional Insights: North America dominated the global market, accounting for a 42.17% share in 2025, owing to the adoption of advanced genomic technologies.

Competitive Players

1. Illumina, Inc.
2. Natera, Inc.
3. Laboratory Corporation of America Holdings
4. Eurofins Scientific
5. Hoffmann-La Roche AG
6. Revvity, Inc.
7. Thermo Fisher Scientific Inc.
8. Agilent Technologies
9. GE HealthCare Technologies Inc.
10. Quest Diagnostics Incorporated
11. Sonic Healthcare Limited
12. CENTOGENE N.V.
13. QIAGEN N.V.
14. PathWest Laboratory Medicine WA
15. Myriad Genetics
16. BGI Genomics Co., Ltd.
17. Invitae Corporation
18. MedGenome
19. Cordlife
20. Others

Recent Developments

Segmentation

1. By Product (2026-2034)
   1. Instrument
      1. Ultrasound Devices
      2. NGS Systems
      3. PCR Instruments
      4. Microarray
      5. Others
   2. Consumables
      1. Assay Kits & Reagents
      2. Disposables
   3. Services
2. By Application (2026-2034)
   1. Trisomy
   2. Microdeletion Syndrome
   3. Others
3. By End User (2026-2034)
   1. Hospitals
   2. Clinics
   3. Diagnostic Laboratories